Trial Profile
Assessment of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Ascending Oral Doses of Various Formulations of PWT-143 in Healthy Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 16 Jun 2021
Price :
$35
*
At a glance
- Drugs Zandelisib (Primary)
- Indications Haematological malignancies
- Focus Adverse reactions; First in man
- Sponsors MEI Pharma
- 09 Jun 2021 According to a MEI Pharma media release, data will be presented at the 16th International Conference on Malignant Lymphoma (16-ICML).
- 01 Nov 2018 Results published in the Clinical Therapeutics
- 28 Aug 2017 Status changed from active, no longer recruiting to completed.